Discovery of a Covalent Inhibitor of Pro-Caspase-1 Zymogen Blocking NLRP3 Inflammasome Activation and Pyroptosis
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Dongyi Cao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Natural Products Research, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China. Hauptthemen laut MEDLINE: Pyroptosis, Caspase 1, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Sichuan University, Chengdu Municipal Institute of Biology, Chinese Academy of Sciences, Science and Technology Department of Sichuan Province.
Abstract (Originalsprache)
Caspase-1 plays a central role in innate immunity, as its activation by inflammasomes induces the production of proinflammatory cytokines and pyroptosis. However, specific inhibition of the enzymatic activity of this protease is not effective in suppressing inflammation, owing to its enzyme-independent function. Herein, we identified a cyclohexenyl isothiocyanate compound (CIB-1476) that potently inhibited caspase-1 activity and suppressed the assembly and activation of the NLRP3 inflammasome and gasdermin-D-mediated pyroptosis. Mechanistically, CIB-1476 directly targeted pro-caspase-1 as an irreversible covalent inhibitor by binding to Cys285 and Cys397, resulting in more durable anti-inflammatory effects in the suppression of enzyme-dependent IL-1β production and enzyme-independent nuclear factor κB activation. Chemoproteomic profiling demonstrated the engagement of CIB-1476 with caspase-1. CIB-1476 showed potent therapeutic effects by suppressing inflammasome activation in mice, which was abolished in Casp1-/- mice. These results warrant further development of CIB-1476 along with its analogues as a novel strategy for caspase-1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Natural Products Research, Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China.
- Department of Pharmacy, Kunming Municipal Hospital of Traditional Chinese Medicine, Kunming 650500, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu 610064, China.
- School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 511400, China.
- State Key Laboratory of Membrane Biology, School of Life Sciences, Institute for Immunology, Beijing Advanced Innovation Center for Structural Biology, Beijing Key Lab for Immunological Research on Chronic Diseases, Bei…
ORCID-Profile: Guolin Zhang, Xiaohua Liu, Shunxi Dong, Xiaoming Feng, Fei Wang
Förderung
- Sichuan University
- Chengdu Municipal Institute of Biology, Chinese Academy of Sciences
- Science and Technology Department of Sichuan Province
- National Natural Science Foundation of China
- Chinese Academy of Sciences
Zitieren
APA
Cao, D., Xi, R., Li, H., Zhang, Z., Shi, X., Li, S., Jin, Y., Liu, W., Zhang, G., Liu, X., Dong, S., Feng, X., & Wang, F. (2024). Discovery of a Covalent Inhibitor of Pro-Caspase-1 Zymogen Blocking NLRP3 Inflammasome Activation and Pyroptosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01558
Vancouver
Cao D, Xi R, Li H, Zhang Z, Shi X, Li S, et al. Discovery of a Covalent Inhibitor of Pro-Caspase-1 Zymogen Blocking NLRP3 Inflammasome Activation and Pyroptosis. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01558
BibTeX
@article{Cao2024,
author = {Cao, Dongyi and Xi, Ruiying and Li, Hongye and Zhang, Zhonghui and Shi, Xiaoke and Li, Shanshan and Jin, Yujie and Liu, Wanli and Zhang, Guolin and Liu, Xiaohua and Dong, Shunxi and Feng, Xiaoming and Wang, Fei},
title = {Discovery of a Covalent Inhibitor of Pro-Caspase-1 Zymogen Blocking NLRP3 Inflammasome Activation and Pyroptosis},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01558}
}
EUVIMED